Marketing applications for two generic versions of the multiple sclerosis blockbuster, Tecfidera, are also under review by the European Medicines Agency.

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Market Snapshot: Acute myeloid leukemia is a serious condition that affects people mainly in late middle age, for which there is a large R&D pipeline of candidate products being researched by pharmaceutical and biotech companies, many of whom are using a targeted medicine approach.

While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.